Piper Sandler Boosts Natera (NASDAQ:NTRA) Price Target to $200.00

Natera (NASDAQ:NTRA) had its price objective increased by Piper Sandler from $150.00 to $200.00 in a report published on Monday morning,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Other equities analysts also recently issued research reports about the company. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. BTIG Research upped their price objective on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. TD Cowen lifted their target price on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $135.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. Finally, The Goldman Sachs Group raised their price objective on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $140.59.

Natera Price Performance

Shares of Natera stock opened at $169.20 on Monday. The company’s fifty day simple moving average is $129.84 and its two-hundred day simple moving average is $117.00. Natera has a 12-month low of $53.62 and a 12-month high of $171.95. The firm has a market cap of $22.34 billion, a PE ratio of -96.14 and a beta of 1.53. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s quarterly revenue was up 63.9% on a year-over-year basis. During the same period last year, the firm earned ($0.95) earnings per share. As a group, equities analysts expect that Natera will post -1.66 EPS for the current year.

Insider Activity

In other news, insider Solomon Moshkevich sold 256 shares of the firm’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total value of $30,737.92. Following the transaction, the insider now directly owns 111,891 shares in the company, valued at $13,434,752.37. This trade represents a 0.23 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Jonathan Sheena sold 2,700 shares of the company’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total value of $344,439.00. Following the sale, the insider now owns 284,741 shares of the company’s stock, valued at approximately $36,324,409.37. This trade represents a 0.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 46,503 shares of company stock valued at $6,325,804 over the last three months. Insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Natera

Large investors have recently made changes to their positions in the company. Itau Unibanco Holding S.A. purchased a new position in shares of Natera in the second quarter worth approximately $28,000. Quarry LP raised its position in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares during the period. GAMMA Investing LLC boosted its stake in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares during the last quarter. Covestor Ltd grew its position in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the period. Finally, True Wealth Design LLC bought a new stake in shares of Natera during the 3rd quarter valued at $57,000. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.